Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

[New drugs: money-back guarantee?].

Steenhoek A, Koopmanschap MA, Franken MG, Rutten FF.

Ned Tijdschr Geneeskd. 2011;155:A2042. Dutch.

PMID:
21262015
2.
3.

Risk-sharing agreements for innovative drugs: a new solution to old problems?

de Pouvourville G.

Eur J Health Econ. 2006 Sep;7(3):155-7. No abstract available.

PMID:
16912890
4.

[Clinical researchers and pharmaceutical industry. Dangerous liaisons].

Roos JC.

Ned Tijdschr Geneeskd. 1999 Aug 7;143(32):1668-71. Dutch.

PMID:
10494304
5.

[Innovative agreements with the pharmaceutical industry: "pay for performance"].

Badia X, Prior M.

Farm Hosp. 2010 Mar-Apr;34(2):53-5. doi: 10.1016/j.farma.2009.12.004. Epub 2010 Mar 6. Spanish. No abstract available.

PMID:
20207566
7.
8.

A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.

Godman B, Gustafsson LL.

Appl Health Econ Health Policy. 2013 Feb;11(1):79-82. doi: 10.1007/s40258-012-0008-7. No abstract available.

PMID:
23322546
9.

Authors' reply to Godman and Gustafsson: "A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing".

Persson U, Svensson J, Pettersson B.

Appl Health Econ Health Policy. 2013 Feb;11(1):83-4. doi: 10.1007/s40258-013-0009-1. No abstract available.

PMID:
23359036
10.

Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.

Neumann PJ, Chambers JD, Simon F, Meckley LM.

Health Aff (Millwood). 2011 Dec;30(12):2329-37. doi: 10.1377/hlthaff.2010.1147.

11.

European healthcare policies for controlling drug expenditure.

Ess SM, Schneeweiss S, Szucs TD.

Pharmacoeconomics. 2003;21(2):89-103.

PMID:
12515571
12.

Should financial incentives be used to differentially reward 'me-too' and innovative drugs?

Pekarsky B.

Pharmacoeconomics. 2010;28(1):1-17. doi: 10.2165/11318770-000000000-00000. Review.

PMID:
20014872
13.

Pharmaceutical risk-sharing agreements.

Cook JP, Vernon JA, Manning R.

Pharmacoeconomics. 2008;26(7):551-6.

PMID:
18563946
14.

Aligning incentives for value-based health care.

Doliveux R.

Health Aff (Millwood). 2012 Apr;31(4):883; author reply 884. doi: 10.1377/hlthaff.2012.0224. No abstract available.

15.

Drug policy: making effective drugs available without bankrupting the healthcare system.

Laupacis A, Anderson G, O'Brien B.

Healthc Pap. 2002;3(1):12-30. Review.

PMID:
12811107
16.

Issues in bringing new drugs to the market.

Ammann AJ.

Science. 2005 Dec 2;310(5753):1425-6; author reply 1425-6. No abstract available.

PMID:
16329171
17.

Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.

Zaric GS, O'brien BJ.

Health Econ. 2005 Aug;14(8):793-803.

PMID:
15685669
18.

Pharmaceutical risk-sharing agreements.

Gandjour A.

Pharmacoeconomics. 2009;27(5):431-2. doi: 10.2165/00019053-200927050-00007. No abstract available.

PMID:
19586080
19.

[A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].

Gustafsson LL, Wettermark B, Kalin M, Korkmaz S, Persson ME, Almkvist H, Hjemdahl P, Julander M, Kristianson K, Ringertz B, Bergen-Dahl GT, Wilking N.

Lakartidningen. 2008 Oct 15-21;105(42):2917-22. Swedish. No abstract available.

PMID:
19025148
20.

New ways of insulin delivery.

Heinemann L.

Int J Clin Pract Suppl. 2010 Feb;(166):29-40. doi: 10.1111/j.1742-1241.2009.02276.x. Review.

PMID:
20377662

Supplemental Content

Support Center